Americas Cancer Immunotherapy Market Research Report –Forecast till 2027

Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), End Users (Hospitals, Academic Institutes) - Forecast till 2027

ID: MRFR/Pharma/0149-HCR | February 2021 | Region: Americas | 90 pages

Americas Cancer Immunotherapy Market Scenario:


Cancer Immunotherapy is a treatment that uses a person’s immune system to fight the diseases. Some types of the cancer immunotherapies are often referred to as biologic therapies or biotherapies. The basic principle of cancer immunotherapy is to enhance a patient’s immune system to fight against cancer. This can be achieved by administrating various immune system components, such as synthesized immune proteins. In recent years, cancer immunotherapy have been extensively exploited for the treatment of the different type cancers including breast, prostate, lung cancer, and others. Increasing prevalence of cancer is one of the major drivers for the Americas cancer immunotherapy market growth during the forecast period. The most commonly prevalent cancers in the U.S. include breast cancer, lung, bronchus cancer, and others. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. Moreover, it was estimated that the national healthcare expenditures for cancer care in the U.S. totalled nearly to USD 125 billion in 2010, and it is expected to reach USD 156 billion by 2020. Moreover, growing geriatric population and rising healthcare expenditure will boost the market growth. Additionally, growing biotech and pharmaceutical industries fuels the market growth during the projected period. However, lack of awareness, restriction in therapeutics against different cancers and high cost for the treatment may restrain the market growth from 2017-2023. 

The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period. 


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 


Figure 1:- Americas cancer immunotherapy market share, by region Americas cancer immunotherapy market


Sources: WHO, annual reports, press release, white paper, and company presentations


Segmentation


The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.


On the basis of the cancer, the Americas cancer immunotherapy market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.


On the basis of the therapeutics, the Americas cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others. The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.


On the basis of the end users, the Americas cancer immunotherapy market is segmented as hospitals & clinics, academic institutes, research organization, and others. 


Regional Analysis 


On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the cancer immunotherapy market growth.


On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population. 


Research Methodology
America Cancer Immunotherapy Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


Key players for the Americas cancer immunotherapy market


Some of the major player in the Americas cancer immunotherapy market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Therapeutics Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. The Americas Cancer Immunotherapy Market, by Cancer

6.1 Introduction

6.2 Lung Cancer

Market Estimates & Forecast, 2020-2027

6.3 Prostate Cancer

Market Estimates & Forecast, 2020-2027

6.4 Colorectal Cancer

Market Estimates & Forecast, 2020-2027

6.5 Head & Neck Cancer

Market Estimates & Forecast, 2020-2027

6.6 Others

Chapter 7. The Americas Cancer Immunotherapy Market, by Therapeutics

7.1 Introduction

7.2 Monoclonal Antibodies

Market Estimates & Forecast, 2020-2027

7.2.1 Naked Monoclonal Antibodies

7.2.1.1 Naked Monoclonal Antibodies

7.2.1.2 Alemtuzumab

7.2.1.3 Trastuzumab

7.2.1.4 Others

7.2.2 Conjugated Monoclonal Antibodies

7.2.3 Chemolabeled Antibodies

7.2.4 Bispecific Monoclonal Antibodies

7.2.5 Others

7.3 Immune Checkpoint Inhibitors

Market Estimates & Forecast, 2020-2027

7.3.1 PD-1 inhibitors

7.3.1.1 Pembrolizumab

7.3.1.2 Nivolumab

7.3.1.3 Others

7.3.2 PD-L1 inhibitors

7.3.2.1 Atezolizumab

7.3.2.2 Avelumab

7.3.2.3 Others

7.4 Vaccines

Market Estimates & Forecast, 2020-2027

7.5 Non-specific cancer immunotherapies and adjuvants

Market Estimates & Forecast, 2020-2027

7.5.1 Cytokines

7.5.2 Interleukins

7.5.3 Others

Chapter 8. The Americas Cancer Immunotherapy Market, by End Users

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, 2020-2027

8.3 Research Organization

Market Estimates & Forecast, 2020-2027

8.4 Retail Pharmacies

Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. The Americas Cancer Immunotherapy Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Cancer Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 AstraZeneca

11.2.1 Company Overview

11.2.2 Cancer Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 F. Hoffmann-La Roche Ltd.

11.3.1 Company Overview

11.3.2 Cancer Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bayer AG

11.4.1 Company Overview

11.4.2 Cancer/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bristol-Myers Squibb Company

11.5.1 Company Overview

11.5.2 Cancer Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Eli Lilly and Company

11.6.1 Company Overview

11.6.2 Cancer Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Merck & Co., Inc.

11.7.1 Overview

11.7.2 Cancer Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Pfizer Inc.

11.8.1 Overview

11.8.2 Cancer Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Novartis AG

11.9.1 Overview

11.9.2 Cancer Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Americas Cancer Immunotherapy Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 The Americas Cancer Immunotherapy Industry Synopsis, 2020-2027

Table 2 The Americas Cancer Immunotherapy Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 The Americas Cancer Immunotherapy Market by Region, 2020-2027, (USD Million)

Table 4 The Americas Cancer Immunotherapy Market by Cancer, 2020-2027, (USD Million)

Table 5 The Americas Cancer Immunotherapy Market by Therapeutics, 2020-2027, (USD Million)

Table 6 The Americas Cancer Immunotherapy Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Americas Cancer Immunotherapy Market

Figure 3 Market Dynamics for the Americas Cancer Immunotherapy Market

Figure 4 The Americas Cancer Immunotherapy Market Share, by Cancer 2020

Figure 5 The Americas Cancer Immunotherapy Market Share, by Therapeutics 2020

Figure 6 The Americas Cancer Immunotherapy Market Share, by End Users, 2020

Figure 7 The Americas Cancer Immunotherapy Market Share, by Region, 2020

Figure 8 The Americas Cancer Immunotherapy Market: Company Share Analysis, 2020 (%)

Figure 9 Amgen Inc.: Key Financials

Figure 10 Amgen Inc.: Segmental Revenue

Figure 11 Amgen Inc.: Geographical Revenue

Figure 12 AstraZeneca: Cancer UK Ltd: Key Financials

Figure 13 AstraZeneca: Cancer UK Ltd: Segmental Revenue

Figure 14 AstraZeneca: Cancer UK Ltd: Geographical Revenue

Figure 15 F. Hoffmann-La Roche Ltd.: Key Financials

Figure 16 F. Hoffmann-La Roche Ltd.: Segmental Revenue

Figure 17 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 18 Bayer AG: Key Financials

Figure 19 Bayer AG: Segmental Revenue

Figure 20 Bayer AG: Geographical Revenue

Figure 21 Bristol-Myers Squibb Company: Key Financials

Figure 22 Bristol-Myers Squibb Company: Segmental Revenue

Figure 23 Bristol-Myers Squibb Company: Geographical Revenue

Figure 24 Eli Lilly and Company: Key Financials

Figure 25 Eli Lilly and Company: Segmental Revenue

Figure 26 Eli Lilly and Company: Geographical Revenue

Figure 27 Merck & Co., Inc.: Key Financials

Figure 28 Merck & Co., Inc.: Segmental Revenue

Figure 29 Merck & Co., Inc.: Geographical Revenue

Figure 30 Pfizer Inc.: Key Financials

Figure 31 Pfizer Inc.: Segmental Revenue

Figure 32 Pfizer Inc.: Geographical Revenue

Figure 33 Novartis AG: Key Financials

Figure 34 Novartis AG: Segmental Revenue

Figure 35 Novartis AG: Geographical Revenue